Codexis Inc
Company Profile
Business description
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.
Contact
200 Penobscot Drive
Redwood CityCA94063
USAT: +1 650 421-8100
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
188
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,169.00 | 11.10 | 0.14% |
| CAC 40 | 8,022.33 | 20.62 | -0.26% |
| DAX 40 | 22,852.66 | 39.02 | -0.17% |
| Dow JONES (US) | 42,583.32 | 597.97 | 1.42% |
| FTSE 100 | 8,638.01 | 8.78 | -0.10% |
| HKSE | 23,387.86 | 517.70 | -2.17% |
| NASDAQ | 18,188.59 | 404.54 | 2.27% |
| Nikkei 225 | 37,769.83 | 161.34 | 0.43% |
| NZX 50 Index | 12,184.51 | 56.30 | 0.46% |
| S&P 500 | 5,767.57 | 100.01 | 1.76% |
| S&P/ASX 200 | 7,944.10 | 7.20 | 0.09% |
| SSE Composite Index | 3,364.05 | 5.98 | -0.18% |